Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie 
Welcome,         Profile    Billing    Logout  
 19 Diseases   1 Trial   1 Trial   3312 News 


«12...56789101112131415...4849»
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Retrospective data, Journal:  Mortality in KPC-producing Klebsiella pneumoniae bloodstream infections: a changing landscape. (Pubmed Central) -  Oct 4, 2023   
    Reduced cefiderocol susceptibility was mediated by mutations in ampC and tonB-dependent receptors. Our results suggest that the increased mortality in CR-Kp BSI compared with CS-Kp BSI is not (or no longer) dependent on the type of therapy in areas where ceftazidime/avibactam-susceptible KPC-producing isolates are the most prevalent type of CR-Kp.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Preclinical, Journal:  In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates. (Pubmed Central) -  Sep 28, 2023   
    CZA was the most active ?-lactam agent against 68.9% of the studied isolates, while amikacin was the most active agent among all comparator antibiotics (80% susceptibility)...CZA is a promising addition to our limited armamentarium against CRE infections, given the reasonably high susceptibility rates against these CRE isolates. Careful stewardship and rational dosing regimens are required to preserve CZA's utility against CRE infections.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Review, Journal:  Carbapenem-Resistant Klebsiella pneumoniae in Large Public Acute-Care Healthcare System, New York, New York, USA, 2016-2022. (Pubmed Central) -  Sep 26, 2023   
    Of 182 isolates with proven or presumptive (ceftazidime/avibactam susceptible) enzymes, 143 were serine carbapenemases; most confirmed cases were K. pneumoniae carbapenemase...Most patients with metallo-?-lactamases originated from long-term care facilities. An aggressive and universal program involving surveillance and isolation will be needed to control the spread of CRKP in the city of New York.
  • ||||||||||  meropenem / Generic mfg., fosfomycin tromethamine / Generic mfg.
    Journal:  Fosfomycin-meropenem synergistic combination against NDM carbapenemase-producing Klebsiella pneumoniae strains. (Pubmed Central) -  Sep 25, 2023   
    In this study, time kill assay showed combination therapies action versus K.pneumoniae metallo-b-lactamase producing (NDM) strains and confirmed the synergistic action of fosfomycin/meropenem combination. In vitro synergy testing should be routinely performed in multidrug resistance infections and combo therapies can be used as a possible alternative in targeted patients with the goal of reducing overall antibiotic costs.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Weighing the Odds: Novel ?-Lactam/?-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese. (Pubmed Central) -  Sep 18, 2023   
    In multivariable analysis, morbid obesity (1.06; 95% CI, 1.02-1.79), prolonged time to BL/BLI initiation (1.47; 95% CI, 1.28-2.66), renal dose-adjusted BL/BLI in the first 48 hours of therapy (1.12; 95% CI, 1.09-1.75), and continuous renal replacement therapy during BL/BLI therapy (1.35; 95% CI, 1.06-1.68) were independently associated with increased odds of presumed treatment failure. Among hospitalized patients receiving BL/BLI for P aeruginosa HABP/VABP, those who were morbidly obese had significantly greater odds of presumed treatment failure when compared with those who were non-morbidly obese.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Guanidinylated Amphiphilic Tobramycin Derivatives Synergize with ?-Lactam/?-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa. (Pubmed Central) -  Sep 11, 2023   
    The optimized guanidinylated tobramycin-biphenyl derivative was noncytotoxic and demonstrated the ability to potentiate ceftazidime and aztreonam monotherapy and in dual combinations with avibactam against multidrug-resistant (MDR) and ?-lactamase harboring isolates of P. aeruginosa. The triple combination of ceftazidime/avibactam plus guanidinylated tobramycin-biphenyl resulted in rapid bactericidal activity within 4-8 h of treatment, demonstrating the potential application of these guanidinylated amphiphilic tobramycin derivatives in augmenting BL/BLI combinations.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Are we looking towards an early demise of ceftazidime/avibactam (CAZ/AVI) as an antibiotic? (Pubmed Central) -  Sep 8, 2023   
    The triple combination of ceftazidime/avibactam plus guanidinylated tobramycin-biphenyl resulted in rapid bactericidal activity within 4-8 h of treatment, demonstrating the potential application of these guanidinylated amphiphilic tobramycin derivatives in augmenting BL/BLI combinations. No abstract available
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal, Gram negative:  Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection. (Pubmed Central) -  Sep 7, 2023   
    Compared with Polymyxin B, CAZ-AVI significantly improved the outcome of mechanical ventilation in patients with septic shock, agranulocytosis, Intensive Care Unit (ICU) patients, bloodstream infection, and patients with SOFA score?>?6, and had a lower incidence of adverse events. We monitored the emergence of CAZ-AVI resistance and should strengthen the monitoring of drug susceptibility in clinical practice and the rational selection of antibiotic regimens to delay the onset of resistance.